There was no difference in GRP78 levels when comparing patients with PAH monotherapy and combination therapy (Monotherapy: 1199 ± 346 ng/ml, combination therapy: 1160 ± 399.8 ng/ml, p = 0.833). The gene discussed is HSPA5; the disease is pulmonary arterial hypertension.